Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 47 papers were listed this time. Here's a few in our areas of research interest:
Hettle R, Wouters H, Ayres J, et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respir Med. 2012 Oct 3. [Epub ahead of print] PubMed PMID: 23040833.
Hannouf MB, Xie B, Brackstone M, et al. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer. 2012 Oct 2;12(1):447. [Epub ahead of print] PubMed PMID: 23031196.
McCullagh L, Walsh C, Barry M. Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting. Pharmacoeconomics. 2012 Oct 1;30(10):941-59. PubMed PMID: 22667458.
Stroupe KT, Lederle FA, Matsumura JS, et al. Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial. J Vasc Surg. 2012 Oct;56(4):901-909.e2. Epub 2012 May 27. PubMed PMID: 22640466.
Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. PubMed PMID: 22359236.
